Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 396.31
HEB's Cash to Debt is ranked higher than
79% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. HEB: 396.31 )
HEB' s 10-Year Cash to Debt Range
Min: 2.31   Max: No Debt
Current: 396.31

Equity to Asset 0.88
HEB's Equity to Asset is ranked higher than
90% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. HEB: 0.88 )
HEB' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.98
Current: 0.88

0.35
0.98
F-Score: 5
Z-Score: -3.22
M-Score: -1.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -9819.57
HEB's Operating margin (%) is ranked higher than
51% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. HEB: -9819.57 )
HEB' s 10-Year Operating margin (%) Range
Min: -12138.52   Max: -33.33
Current: -9819.57

-12138.52
-33.33
Net-margin (%) -9305.98
HEB's Net-margin (%) is ranked higher than
50% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. HEB: -9305.98 )
HEB' s 10-Year Net-margin (%) Range
Min: -10816.67   Max: -60
Current: -9305.98

-10816.67
-60
ROE (%) -53.86
HEB's ROE (%) is ranked higher than
61% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. HEB: -53.86 )
HEB' s 10-Year ROE (%) Range
Min: -217.32   Max: -20.44
Current: -53.86

-217.32
-20.44
ROA (%) -45.19
HEB's ROA (%) is ranked higher than
59% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. HEB: -45.19 )
HEB' s 10-Year ROA (%) Range
Min: -143.93   Max: -18.36
Current: -45.19

-143.93
-18.36
ROC (Joel Greenblatt) (%) -149.82
HEB's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. HEB: -149.82 )
HEB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9600   Max: -143.23
Current: -149.82

-9600
-143.23
» HEB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

HEB Guru Trades in Q2 2013

Jim Simons 94,000 sh (-27.86%)
» More
Q3 2013

HEB Guru Trades in Q3 2013

Jim Simons 367,200 sh (+290.64%)
» More
Q4 2013

HEB Guru Trades in Q4 2013

Jim Simons 113,000 sh (-69.23%)
» More
Q1 2014

HEB Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HEB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.94
HEB's P/B is ranked higher than
91% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. HEB: 1.94 )
HEB' s 10-Year P/B Range
Min: 0.67   Max: 20.43
Current: 1.94

0.67
20.43
EV-to-EBIT -1.99
HEB's EV-to-EBIT is ranked higher than
77% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HEB: -1.99 )
HEB' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.99

Current Ratio 4.92
HEB's Current Ratio is ranked higher than
76% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. HEB: 4.92 )
HEB' s 10-Year Current Ratio Range
Min: 1.36   Max: 44.82
Current: 4.92

1.36
44.82
Quick Ratio 4.92
HEB's Quick Ratio is ranked higher than
77% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. HEB: 4.92 )
HEB' s 10-Year Quick Ratio Range
Min: 1.36   Max: 44.19
Current: 4.92

1.36
44.19

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.44
HEB's Price/Net Cash is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. HEB: 3.44 )
HEB' s 10-Year Price/Net Cash Range
Min: 1.08   Max: 231.25
Current: 3.44

1.08
231.25
Price/Net Current Asset Value 3.44
HEB's Price/Net Current Asset Value is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. HEB: 3.44 )
HEB' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 231.25
Current: 3.44

1.03
231.25
Price/Tangible Book 2.07
HEB's Price/Tangible Book is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. HEB: 2.07 )
HEB' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 231.25
Current: 2.07

0.72
231.25
Earnings Yield (Greenblatt) 186.90
HEB's Earnings Yield (Greenblatt) is ranked higher than
94% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. HEB: 186.90 )
HEB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 532.3
Current: 186.9

1.6
532.3
Forward Rate of Return (Yacktman) -31.19
HEB's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. HEB: -31.19 )
HEB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -176   Max: -32.9
Current: -31.19

-176
-32.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXB.Germany
Hemispherx Biopharma, Inc. is a Delaware Corporation founded in the early 1970s. The company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2012, the Company had 20 patents worldwide with 70 additional pending patent applications comprising its intellectual property. Its potential competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.
» More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody... Sep 15 2014
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their... Sep 10 2014
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases... Sep 08 2014
Hemispherx Biopharma to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in... Sep 03 2014
HEMISPHERX BIOPHARMA INC Financials Aug 19 2014
Hemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2014 Aug 11 2014
HEMISPHERX BIOPHARMA INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against... Aug 04 2014
Shareholder Suit Involving Loser-Pays Provision Heats Up in Delaware Jul 22 2014
Hemispherx achieves high ranking in sensitivity testing against MERS/SARS Jul 22 2014
Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to... Jul 22 2014
Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on... Jul 14 2014
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... Jul 10 2014
Hemispherx, Bioclones to collaborate on HIV/AIDS eradication Jul 08 2014
Hemispherx Biopharma and Bioclones Join Forces in Effort to Eradicate HIV/AIDS Virus Based on Recent... Jul 08 2014
Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26 Jun 25 2014
Hemispherx confirms Alferon N inhibits replication of MERS virus in vitro Jun 03 2014
Hemispherx receives new U.S. composition of matter patent covering Ampligen May 27 2014
HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 27 2014
Hemispherx, GP Pharm agree to establish manufacturing operation in Argentina May 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK